Benefit of 3-D Planning in Total Hip Replacement. A Prospective Randomized Study

Sponsor
Balgrist University Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05120063
Collaborator
Symbios Orthopedie SA (Industry)
133
4
211.9

Study Details

Study Description

Brief Summary

In this prospective randomized four-armed study the investigators aim to compare wheter 3-D planning, which necessitates preoperative CT acquisition and sophisticated planning together with engineers, results in measurable benefits in terms of objective and subjective outcome values in a collective of patients undergoing primary total hip replacement.

Hypothesis:
  1. When compared to 2-D planning, 3-D planning of a THR results in better hip reconstruction, better subjective and clinical outcome and better longevity of total hip implants.

  2. When compared to a non-anatomical stem, an anatomical stem allows better hip reconstruction, better subjective and clinical outcome and better longevity of total hip implants.

Condition or Disease Intervention/Treatment Phase
  • Device: SPS monoblock stem, Symbios
  • Device: Quadra-H, Medacta
  • Procedure: 3D planning of THR
  • Procedure: 2D planning of THR
N/A

Detailed Description

Patients sent to our outpatient clinic for eventual primary THR are informed about this study and written patient information given to them. When patients decide to undergo primary total hip replacement, patient's questions with respect to this study are discussed in the outpatient clinic and patients willing to participate included.

Block randomization using closed envelopes for age categories 40-50, 50-60, 60-70 years will be conducted to assign the participant to one of the four study arms.

Patients will be blinded for the type of stem and method of planning. Investigators are blined in terms of methods of planning. In terms of stem design, investigators can not be blinded since their visibility on x-ray does not allow it.

The preoperative investigation includes routine investigation and an additional CT scan plus evaluation of the "University of California at Los Angeles" (UCLA) activity level and "Short Form Health 36" (SF-36) score. The same applies for the postoperative investigation and 3 months. The follow-up visits at 1, 5 and 10 years are routine investigations with additional UCLA and SF-36 Scores.

Study Design

Study Type:
Interventional
Actual Enrollment :
133 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Benefit of 3-D Planning in Total Hip Replacement. A Prospective Randomized Study
Actual Study Start Date :
Jun 1, 2012
Anticipated Primary Completion Date :
Jan 28, 2030
Anticipated Study Completion Date :
Jan 28, 2030

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3D anatomical stem

3-D-Planing with anatomical stem (SPS monoblock stem, Symbios)

Device: SPS monoblock stem, Symbios
hip prosthesis

Procedure: 3D planning of THR
primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)

Experimental: 3D non-anatomical stem

3-D-Planing with non anatomical stem (Quadra-H, Medacta)

Device: Quadra-H, Medacta
hip prosthesis

Procedure: 3D planning of THR
primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)

Experimental: 2D anatomical stem

2-D-Planing with anatomical stem (SPS monoblock stem, Symbios)

Device: SPS monoblock stem, Symbios
hip prosthesis

Procedure: 2D planning of THR
primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)

Experimental: 2D non anatomical stem

2-D-Planning with non anatomical Stem (Quadra-H, Medacta)

Device: Quadra-H, Medacta
hip prosthesis

Procedure: 2D planning of THR
primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)

Outcome Measures

Primary Outcome Measures

  1. Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [Change from basline to one year]

    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients, including pain, stiffness, and physical functioning of the hip. A difference in WOMAC of 2.5 points is considered relevant. 3-D-planing and/or anatomical stems will be considered superior to 2-D-planing and /or non-anatomical stems if the one year WOMAC significantly differs by 2.5.

  2. Change in subjective hip value (SHV) [Change from basline to one year]

    The subjective hip value (SHV) is as a patient-reported outcome measurement (PROM) which is reported by the patient. It is easily and quickly performed and interpreted. The SHV is defined as a patient's subjective hip satisfaction expressed as a percentage of 100%, which is the score that an entirely normal hip joint would reach. A difference in subj. hip value of 25% is considered relevant. 3-D-planing and/or anatomical stems will be considered superior to 2-D-planing and /or non-anatomical stems if the one year subjective hip value significantly differs by 25%.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients aged 40-70 years scheduled for primary THR

  • signed written informed consent.

Exclusion Criteria:
  • Charnley class B and C

  • ASA score >2

  • pregnancy

  • gross hip deformity making complex hip reconstruction (greater trochanter advancement, acetabular augmentation, femoral osteotomy, use of cemented or revision stem) necessary

  • immature patients and patients incompetent to judge

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Balgrist University Hospital
  • Symbios Orthopedie SA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Balgrist University Hospital
ClinicalTrials.gov Identifier:
NCT05120063
Other Study ID Numbers:
  • KEK Nr. 2012-0064
First Posted:
Nov 15, 2021
Last Update Posted:
Nov 15, 2021
Last Verified:
Oct 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 15, 2021